Drug Development

Articles

The provider of plant-based ingredients will present recently launched multi-compendial materials for upstream and downstream biopharmaceutical applications.

Roquette Showcases Biopharma Innovations at CPhI Worldwide 2018

The collaboration will focus on developing manufacturing solutions for biosimilars.

Pall and Aetos Biologics Partner on Biosimilar Manufacturing

The collaboration will explore the potential of Dyadic’s gene-expression platform to produce multiple biologic vaccines and drugs.

Sanofi Partners with Dyadic to Research Fungus-Based Expression Platform

As it investigates the root cause of an impurity discovered in valsartan, FDA extends its studies to APIs with similar synthesis processes.

FDA Expands NDMA Investigation to All ARB Class Drugs

Adeline Siew is editor for Pharmaceutical Technology Europe. She is also science editor for Pharmaceutical Technology.

The level of tastemasking required will depend on the API properties and the dosage form design.

Coating for Tastemasking

Cynthia A. Challener is a contributing editor to Pharmaceutical Technology.

Existing software tools cannot take into account the complexity of disease.

Can Artificial Intelligence Take the Next Step for Drug Repositioning?

Milind K. Biyani, PhD, is R&D consultant at Aspire Advisors Pvt. Ltd.

Thixotropic gels, thermosoftened systems, and self-emulsifying systems have expanded the range of potential excipients for liquid-filled hard capsules (LFHC).

Selecting Excipients for Liquid-Filled Hard Capsules

Immobilizing the antibodies on a solid-phase support, such as a resin, and carrying out the conjugation of the payload-linker while the antibodies are bound to that support will prevent aggregation at its source.

Tackling Aggregation Challenges in ADC Production

Amina Faham is global associate director at The Dow Chemical Company.

True Rogers is R&D Technologies leader at The Dow Chemical Company.

Kathryn Hewlett is an Application Development & Innovation scientist at The Dow Chemical Company.

Commonly referred to as the future of advanced pharmaceutical manufacturing, continuous manufacturing has gained major traction in the past 10 years to enable significant improvements in efficiency, safety, cost, and speed to market.

Paving the Way for Modernized Drug-Product Manufacturing Through Excipients

Ralph D. Lindblad, ASQ CQA, is product quality manager, Catalent Pharma Solutions.

David B. Klug is vice-chair of user relations at IPEC-Americas.

Douglas G. Muse is consultant—Compendial Affairs, Eli Lilly & Co.

Phyllis Walsh is associate director of Merck and Company, Inc.

Katherine L. Ulman is president of KLU Consulting.

Priscilla Zawislak is global regulatory affairs advocacy manager, DuPont Nutrition & Biosciences

Increasingly stringent audit requirements will make third-party accredited GMP audits critical for pharmaceutical excipients and raw materials.

APIs and Excipients